pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
CAIN457E22101
Phase 1 · other · Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)
CAIN457E22101 for Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA) is a Phase 1 program (other) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CAIN457E22101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Modality
- other
- Indication
- Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)
- Status
- active
- Trials
- 1